New study investigates hormone Therapy's impact on endometriosis pain
NCT ID NCT07100782
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This study aims to understand how a hormone-suppressing drug (Relugolix Combination Therapy) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis. Researchers will measure changes in blood markers and brain activity to see how the treatment works. The study involves 130 premenopausal women aged 18-49 who have been diagnosed with endometriosis and have had pelvic pain for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.